In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Rocket Pharmaceuticals, with a price target of $9.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cory Jubinville, PhD has given his Buy rating due to a combination of factors including Rocket Pharmaceuticals’ regained momentum and strategic progress in their pipeline. The company has achieved significant milestones such as aligning with the FDA to resume the pivotal Phase 2 trial for RP-A501 in Danon disease, and the FDA’s acceptance of the BLA resubmission for KRESLADI for LAD-I, which is a positive indicator for future approvals.
Additionally, Rocket Pharmaceuticals has shown disciplined execution and strategic focus across its cardiovascular portfolio, with continued FDA engagement on RP-A601 and the initiation of a Phase 1 study for RP-A701. The company’s financial position is also strong, with cash and investments providing an operational runway into Q2 2027, which supports its ongoing and future projects. These factors collectively contribute to the positive outlook and the Buy rating for Rocket Pharmaceuticals’ stock.